Lexicon Lands up to $1B Novo Nordisk Deal for LX9851 Obesity Game-Changer

March 28, 2025

DENVER, Colo., Mar 28, 2025 (247marketnews.com)- Lexicon Pharmaceuticals (NASDAQ:LXRX) just inked a blockbuster deal with Novo Nordisk, handing over the keys to LX9851, a first-in-class oral non-incretin obesity drug, in an exclusive worldwide license worth up to $1 billion. Announced today, the pact nets Lexicon $75 million upfront and near-term milestone cash, with the potential for a $1 billion in development, regulatory, and sales payouts—plus tiered royalties on every sale.

Mike Exton, Ph.D., Lexicon’s CEO and director, stated, “We are thrilled that Novo Nordisk, a global leader in diabetes care and obesity management, has recognized the potential of LX9851. This arrangement decisively strengthens our financial position, providing optionality as we further invest and accelerate our R&D portfolio.”

LX9851, Lexicon’s brainchild, is a potent oral inhibitor of Acyl-CoA Synthetase 5 (ACSL5)—a fat-regulating powerhouse that tweaks energy balance and fires up the ileal brake to curb appetite and slow digestion. Preclinical data from Obesity Week 2024 lit up the charts: paired with semaglutide, LX9851 slashed weight, appetite, and fat mass beyond semaglutide’s solo punch. Post-semaglutide, it tamed weight regain and eased liver fat—a double whammy for the $100 billion obesity market.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LXRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.